Sage Journals: Discover world-class research

Abstract

Objective:

This study explored the role of monocarboxylate transporter 1 (MCT1) in nasopharyngeal carcinoma (NPC) metastasis and its regulation via DNA methyltransferase 3B (DNMT3B)-mediated methylation, to identify therapeutic targets for NPC.

Methods:

MCT1/DNMT3B expression was analyzed in NPC (n = 30) and normal tissues (n = 30) using quantitative polymerase chain reaction (qPCR) and immunohistochemistry. DNMT3B overexpression plasmids were transfected into NPC cells to assess MCT1 expression and promoter methylation via bisulfite sequencing PCR. Luciferase and chromatin immunoprecipitation (ChIP) assays identified DNMT3B-MCT1 promoter interactions. Migration/invasion assays and Western blot evaluated functional impacts of MCT1 silencing on metastasis-related pathways. Bioinformatic validation utilized GEO datasets.

Results:

MCT1 mRNA/protein levels were significantly elevated in NPC versus normal tissues (***p < 0.001), whereas DNMT3B was downregulated. DNMT3B overexpression reduced MCT1 expression (*p < 0.05) and increased MCT1 promoter methylation (**p < 0.01). Luciferase assays revealed that DNMT3B suppressed wild-type MCT1 promoter activity, dependent on an 80 bp CpG island (**p < 0.01). ChIP confirmed DNMT3B enrichment at hypermethylated MCT1 promoter regions (**p < 0.01). MCT1 silencing inhibited NPC cell migration/invasion (*p < 0.05) and downregulated p-AKT, p-mTOR, and p-NFκB (*p < 0.05). High MCT1 correlated with Epstein–Barr virus (EBV)-associated EBNA1BP2 (**p < 0.01), but not PD-L1 markers. DNMT3B inversely correlated with MCT1 (*p < 0.05) and was upregulated in advanced-stage NPC (Stage III + IV vs. I + II, ***p < 0.001), indicating stage-specific epigenetic dysregulation.

Conclusion:

MCT1 promotes NPC metastasis via NF-κB and PI3K/AKT/mTOR pathways, regulated by DNMT3B-driven promoter methylation. The MCT1-DNMT3B axis, linked to EBV-associated metabolic reprogramming, represents a prognostic biomarker and therapeutic target for advanced NPC.

Get full access to this article

View all access options for this article.

References

Bray

, Ferlay

, Soerjomataram

, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68(6):394–424; doi: 10.3322/caac.21492

Ruuskanen

, Leivo

, Minn

, et al. Expression of toll-like receptors in non-endemic nasopharyngeal carcinoma. BMC Cancer, 2019; 19(1):624; doi: 10.1186/s12885-019-5816-9

Tsao

, Yip

, Tsang

, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol, 2014; 50(5):330–338; doi: 10.1016/j.oraloncology.2014.02.006

Zhang

, Wen

, Liu

, et al. Correction to: Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. J Exp Clin Cancer Res, 2021; 40(1):394; doi: 10.1186/s13046-017-0621-2

Felmlee

, Jones

, Rodriguez-Cruz

, et al. Monocarboxylate transporters (SLC16): function, regulation, and role in health and disease. Pharmacol Rev, 2020; 72(2):466–485; doi: 10.1124/pr.119.018762

Bruce

, Yip

, Bratman

, et al. Nasopharyngeal cancer: Molecular landscape. J Clin Oncol, 2015; 33(29):3346–3355; doi: 10.1200/JCO.2015.60.7846

, Zhou

, Xu

, et al. Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling. Cancer Lett, 2020; 478:93–106; doi: 10.1016/j.canlet.2020.03.004

Ren

, Wen

, Li

Y-Q

, et al. TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma. J Exp Clin Cancer Res, 2018; 37(1):227; doi: 10.1186/s13046-018-0881-5

Chen

Y-P

, Chan

ATC

, Le

Q-T

, et al. Nasopharyngeal carcinoma. Lancet, 2019; 394(10192):64–80; doi: 10.1016/S0140-6736(19)30956-0

10.

Payen

, Mina

, Van Hee

, et al. Monocarboxylate transporters in cancer. Mol Metab, 2020; 33:48–66; doi: 10.1016/j.molmet.2019.07.006

11.

Pinheiro

, Reis

, Ricardo

, et al. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol, 2010; 2010:427694; doi: 10.1155/2010/427694

12.

Zhao

, Yan

, Hu

, et al. Differentiated cancer cell-originated lactate promotes the self-renewal of cancer stem cells in patient-derived colorectal cancer organoids. Cancer Lett, 2020; 493:236–244; doi: 10.1016/j.canlet.2020.08.044

13.

Doyen

, Trastour

, Ettore

, et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Biophys Res Commun, 2014; 451(1):54–61; doi: 10.1016/j.bbrc.2014.07.050

14.

Singh

, Afonso

, Sharma

, et al. Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics? Semin Cancer Biol, 2023; 90:1–14; doi: 10.1016/j.semcancer.2023.01.007

15.

Jiang

, Huang

, Jiang

, et al. Lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer. Front Oncol, 2021; 11:647559; doi: 10.3389/fonc.2021.647559

16.

, Zhan

, Dong

, et al. Tumor-derived exosome-educated hepatic stellate cells regulate lactate metabolism of hypoxic colorectal tumor cells via the IL-6/STAT3 pathway to confer drug resistance. Onco Targets Ther, 2020; 13:7851–7864; doi: 10.2147/OTT.S253485

17.

Lee

, Nestler

, Chiappinelli

. Therapeutic targeting of DNA methylation alterations in cancer. Pharmacol Ther, 2024; 258:108640; doi: 10.1016/j.pharmthera.2024.108640

18.

Yang

, Han

, De Carvalho

, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell, 2014; 26(4):577–590; doi: 10.1016/j.ccr.2014.07.028

19.

Lockwood

, Zejnullahu

, Bradner

, et al. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A, 2012; 109(47):19408–19413; doi: 10.1073/pnas.1216363109

20.

Cheng

, Huang

, Zhang

, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nat Commun, 2020; 11(1):1880; doi: 10.1038/s41467-020-15819-3

21.

Tsang

, Lui

VWY

, Bruce

, et al. Translational genomics of nasopharyngeal cancer. Semin Cancer Biol, 2020; 61:84–100; doi: 10.1016/j.semcancer.2019.09.006

22.

, Cai

, Li

, et al. Rediscovery of NF-κB signaling in nasopharyngeal carcinoma: How genetic defects of NF-κB pathway interplay with EBV in driving oncogenesis? J Cell Physiol, 2018; 233(8):5537–5549; doi: 10.1002/jcp.26410

23.

Krook

, Reeser

, Ernst

, et al. Fibroblast growth factor receptors in cancer: Genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer, 2021; 124(5):880–892; doi: 10.1038/s41416-020-01157-0

24.

Popova

, Jücker

. The role of mTOR signaling as a therapeutic target in cancer. Int J Mol Sci, 2021; 22(4):1743; doi: 10.3390/ijms22041743

25.

Murugan

. mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol, 2019; 59:92–111; doi: 10.1016/j.semcancer.2019.07.003

26.

J-H

, Chen

, Yu

J-Y

, et al. PI3K-PKB-mTOR hyperactivation in relation to nasopharyngeal carcinoma progression and prognosis. J Cell Biochem, 2019; 120(6):10186–10194; doi: 10.1002/jcb.28303

27.

, Deng

N-H

, He

X-S

, et al. Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma. Biomark Res, 2022; 10(1):52; doi: 10.1186/s40364-022-00397-x

Mechanism of Monocarboxylate Transporter 1 and Its Methylation in Nasopharyngeal Carcinoma Pathogenesis